Skip to main content
SpringerLink
Log in

Bivalirudin costs made out in ACUITY

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Pinto DS, Stone GW, York M, Reynolds MR, McLaurin BT, Cox DA, Schneider EA, Shi C, Walczak J, Machon DA, Berezin RH, Mehran R, Ohman EM, Lincoff AM, Cohen DJ.Economic evaluation of bivalirudin with or without glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for early invasive management of acute coronary syndromes. Journal of the American College of Cardiology 51 (Spec. issue A): 219 (plus poster) abstr. 1024-71, No. 10, 11 Mar 2008

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bivalirudin costs made out in ACUITY. Pharmacoecon. Outcomes News 550, 8 (2008). https://doi.org/10.2165/00151234-200805500-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805500-00014

Keywords

Search

Navigation